BioXcell 熱銷產(chǎn)品--InVivoPlus rat IgG2a isotype control

產(chǎn)品描述：

BioXcell nVivoPlus rat IgG2a isotype control克隆號(hào)為2A3的同型對(duì)照抗體與三-硝-基-苯-酚反應(yīng)。因?yàn)椴溉閯?dòng)物不表達(dá)三-硝-基-苯-酚，因此該抗體非常適合在大多數(shù)體內(nèi)和體外應(yīng)用中用作大鼠IgG2a抗體的同型對(duì)照。

產(chǎn)品詳情：

為什么選擇InVivoPlus抗體？

InVivoPlus級(jí)別的產(chǎn)品內(nèi)毒素含量更低，經(jīng)過(guò)多種實(shí)驗(yàn)驗(yàn)證，更適合用于體內(nèi)實(shí)驗(yàn)研究

該產(chǎn)品自上市已被多篇SCI文獻(xiàn)引用，品質(zhì)有保證，以下是部分已發(fā)表的文獻(xiàn)引用：

文章

1.Bauche, D., et al. (2018). 'LAG3(+) Regulatory T Cells Restrain Interleukin-23-Producing CX3CR1(+) Gut-Resident Macrophages during Group 3 Innate Lymphoid Cell-Driven Colitis' Immunity 49(2): 342-352 e345.

2.Ngiow, S. F., et al. (2015). 'A Threshold Level of Intratumor CD8+ T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1' Cancer Res 75(18): 3800-3811.

3.Dai, M., et al. (2015). 'Curing mice with large tumors by locally delivering combinations of immunomodulatory antibodies' Clin Cancer Res 21(5): 1127-1138.

4.Kurtulus, S., et al. (2015). 'TIGIT predominantly regulates the immune response via regulatory T cells' J Clin Invest. doi : 10.1172/JCI81187.

5.Ellis, G. T., et al. (2015). 'TRAIL+ monocytes and monocyte-related cells cause lung damage and thereby increase susceptibility to influenza-Streptococcus pneumoniae coinfection' EMBO Rep 16(9): 1203-1218.

更多產(chǎn)品詳情請(qǐng)聯(lián)系 BioXcell 中國(guó)授權(quán)代理——欣博盛生物